Propeller Health has extended its 2015 collaboration with GlaxoSmithKline (GSK) to improve management of asthma and COPD, the company announced recently.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US,” Propeller CEO David Van Sickle said in a statement.
According to a release, the companies will prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler.
To date, the Propeller platform has been used by patients and physicians in more than 55 commercial programs in the United States. View the story here.